EP4023250A1 — Dual mode radiotracer and -therapeutics
Assigned to Technische Universitaet Muenchen · Expires 2022-07-06 · 4y expired
What this patent protects
The present disclosure relates to compounds of Formula (1a), (1b), (1c) or (1d):and pharmaceutically acceptable salts thereof, wherein X, Z, L, CM and R<sup>1</sup> are defined herein, and their use as cancer diagnostic or imaging agents.
USPTO Abstract
The present disclosure relates to compounds of Formula (1a), (1b), (1c) or (1d):and pharmaceutically acceptable salts thereof, wherein X, Z, L, CM and R<sup>1</sup> are defined herein, and their use as cancer diagnostic or imaging agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.